taqman gene expression assays specific cip2a pp2a (Thermo Fisher)
Structured Review

Taqman Gene Expression Assays Specific Cip2a Pp2a, supplied by Thermo Fisher, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/cip2a+expression/pmc04414191-293-39-42
Average 90 stars, based on 1 article reviews
Images
1) Product Images from "PP2A inhibition determines poor outcome and doxorubicin resistance in early breast cancer and its activation shows promising therapeutic effects"
Article Title: PP2A inhibition determines poor outcome and doxorubicin resistance in early breast cancer and its activation shows promising therapeutic effects
Journal: Oncotarget
doi:
Figure Legend Snippet: (A) Quantification of PP2A activity and western blot showing levels of immunoprecipitated PP2A from the protein extracts used in the phosphatase assays. (B) Western blot analysis showing PP2A, phospho-PP2A, CIP2A and SET expression levels; * p < 0.05; ** p < 0.01; N1–3: normal controls corresponding to normal mammary tissue samples obtained from Fundación Jiménez Díaz Biobank (Madrid, Spain).
Techniques Used: Activity Assay, Western Blot, Immunoprecipitation, Expressing
Figure Legend Snippet: (A) Tumor growth and statistical analysis between control, FTY720, doxorubicin and FTY720+doxorubicin groups of treatment (B) Immunohistochemical detection of CIP2A, SET, p-PP2A, p-Histone H3 and cleaved-Caspase 3 expression in tumor samples from the different groups of treatment. (C) Evaluation of differential expression of CIP2A, SET, p-PP2A, p-Histone H3 and cleaved-Caspase 3.
Techniques Used: Immunohistochemical staining, Expressing
Figure Legend Snippet: (A) Immunohistochemical detection of CIP2A, p-PP2A and SET showing positive and negative staining. The line shows 25 μm. Magnification x400. Kaplan-Meier analyses of overall survival (B) and event-free survival (C) in a cohort of 230 breast cancer patients.
Techniques Used: Immunohistochemical staining, Negative Staining
Related Articles
Amplification:Article Title: PP2A inhibition determines poor outcome and doxorubicin resistance in early breast cancer and its activation shows promising therapeutic effects Article Snippet: Then, RNA was reversely transcribed to cDNA using Transcriptor Universal cDNA Master (Roche Life Science). Real-time Polymerase Chain Reaction:Article Title: PP2A inhibition determines poor outcome and doxorubicin resistance in early breast cancer and its activation shows promising therapeutic effects Article Snippet: Then, RNA was reversely transcribed to cDNA using Transcriptor Universal cDNA Master (Roche Life Science). Expressing:Article Title: PP2A inhibition determines poor outcome and doxorubicin resistance in early breast cancer and its activation shows promising therapeutic effects Article Snippet: Then, RNA was reversely transcribed to cDNA using Transcriptor Universal cDNA Master (Roche Life Science). Activity Assay:Article Title: PP2A inhibition determines poor outcome and doxorubicin resistance in early breast cancer and its activation shows promising therapeutic effects Article Snippet: Then, RNA was reversely transcribed to cDNA using Transcriptor Universal cDNA Master (Roche Life Science). Western Blot:Article Title: PP2A inhibition determines poor outcome and doxorubicin resistance in early breast cancer and its activation shows promising therapeutic effects Article Snippet: Then, RNA was reversely transcribed to cDNA using Transcriptor Universal cDNA Master (Roche Life Science). Immunoprecipitation:Article Title: PP2A inhibition determines poor outcome and doxorubicin resistance in early breast cancer and its activation shows promising therapeutic effects Article Snippet: Then, RNA was reversely transcribed to cDNA using Transcriptor Universal cDNA Master (Roche Life Science). Immunohistochemical staining:Article Title: PP2A inhibition determines poor outcome and doxorubicin resistance in early breast cancer and its activation shows promising therapeutic effects Article Snippet: Then, RNA was reversely transcribed to cDNA using Transcriptor Universal cDNA Master (Roche Life Science). Negative Staining:Article Title: PP2A inhibition determines poor outcome and doxorubicin resistance in early breast cancer and its activation shows promising therapeutic effects Article Snippet: Then, RNA was reversely transcribed to cDNA using Transcriptor Universal cDNA Master (Roche Life Science). |
